Slide 1: Investor Conference Call Q4 and Fiscal Year 2018
Investor Conference Call Q4 and Fiscal Year 2018 August 28, 2018
Slide 2: Forward Looking Statement
Forward Looking Statement The following material is of a general nature and has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or
Slide 3: Digital Health Company Focused on Medication Adherence
Digital Health Company Focused on Medication Adherence Chronic Disease Platform Validated in Respiratory Disease Proprietary and Protected 14 Patent Families Across US, EU, China, Japan, AU, NZ Robust Clinical Evidence 30 Trials in 40 Countries 72+ Peer-Reviewed Publications Regulatory Success Clear
Slide 4: Delivering on Guidance – Accelerating Growth
Delivering on Guidance – Accelerating Growth Goal: Ship a minimum of 25,000 Hailie sensors ü We shipped over 25,000 Hailie sensors to AstraZeneca and 27,000 Hailie sensors overall, a significant increase from the 18,000 sensors shipped in FY17 Goal: Obtain FDA 501(k) clearance to market SmartTouch f
Slide 5: Fiscal 2018 Milestones and Recent Highlights
Fiscal 2018 Milestones and Recent Highlights • Shipped 27,000 Hailie™ sensors, a 49.1% year-over-year increase Global • Significant increase in commercial rollouts of SmartTurbo™ in Europe and Australia Expansion • Strong clinical results published in peer reviewed journals support additional regula
Slide 6: Financial Results Review
Financial Results Review Adherium Ltd ©2018 6
Slide 7: FY 2018 Financial Results
FY 2018 Financial Results 12 months to 12 months to Change % on comparable June 30, 2018 June 30, 2017 period basis Revenue $5.9m $2.3m 150% increase Gross profit $4.8 $1.2m 311% increase 81% margin 49% margin Other income (grants and interest) $0. 8m $1.0m 21% decrease Operating expenses $14.9m $15
Slide 8: Fourth Quarter 2018 Cash Flows
Fourth Quarter 2018 Cash Flows 3 months to 3 months to Change % June 30, 2018 March 31, 2018 Receipts from customers $2.2m $2.0m 12% increase Staff costs $2.0m $1.6m 20% decrease Other operating cash outflows (net) $1.6m $1.4m 19% decrease Total operating cash outflows $1.3m $1.0m 35% increase As at
Slide 9: Growth Strategies and Outlook
Growth Strategies and Outlook Adherium Ltd ©2018 9
Slide 10: Market Channel Direct to Payer and Provider
Strategic Priorities • US is ~40m patient and an estimated $34B in avoidable healthcare costs • B2B sales with initial focus on smaller, self-contained insurance systems for more rapid adoption and in market economic validation • Larger self-insured corporations focused on lowering cost of coverage
Slide 11: Market Channel Direct to Consumer (DtC)
Strategic Priorities • Focus initially on US market (~40m Asthma and COPD patients) • Direct, digital only marketing • Highly targeted customer acquisition strategy • Subscription offering Commercial Launches Market Channel • New Zealand and U.S. • SaaS - monthly subscription, including device and u
Slide 12: Market Channel Biopharmaceutical Partners
Strategic Priorities • Increasing volume in existing Hailie product lines by launching into new large markets • Expanding product range leveraging existing OEM partnerships (beyond Symbicort®) • Opportunistically evaluating new OEM distribution agreements AstraZeneca • First commercial shipments in
Slide 13: Summary and Guidance
Summary and Guidance Commitment Committed to $500B+ opportunity in medication adherence Extend the reach of our Hailie platform and grow subscriber base to 20,000 subscribers across Execution our Direct-to-Consumer and Direct-to Payer channels • Continued strong revenue growth FY19 FY19 Guidance • M
Slide 14: Thank You
adherium% Adherium THANK YOU